The FASEB Journal
May 1, 2022
Suzanne Underhill, Susan Amara
The use of 3,4‐methylenedioxymethamphetamine (MDMA) has recently gained interest as a potential therapeutic tool for the treatment of post‐traumatic stress disorder (PTSD). However, the mechanism of action of this drug has not yet been fully elucidated. Here we demonstrate that MDMA acts by targeting the trace amine associated receptor 1 (TAAR1), an intracellular G‐protein coupled receptor...
Journal of Psychiatric Research
May 1, 2022
Timothy D Brewerton, Julie B. Wang, Adele Lafrance et al.
81 citations
Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there are no proven integrative treatment modalities for ED-PTSD. In clinical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the treatment of PTSD and may be promising for ED-PTSD. Ninety individuals with severe PTSD received treatment in a double-blind, placebo-controlled pivotal trial...
Human Psychopharmacology: Clinical and Experimental
May 1, 2022
Jason B. Luoma, Ben Shahar, M Kati Lear et al.
26 citations
Researchers have suggested that psychotherapy may be enhanced by the addition of 3,4-methylenedioxymethamphetamine (MDMA), particularly in the treatment of disorders wherein interpersonal dysfunction is central, such as social anxiety disorder. We review literature pertaining to three potential processes of change that may be instigated during sessions involving MDMA administration in the...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
April 29, 2022
Mihai Avram, Felix Müller, Helena Rogg et al.
43 citations
Psychedelics, empathogens, and psychostimulants evoke thalamocortical hyperconnectivity with sensorimotor areas, akin to findings in patients with psychotic disorders.
JAMA Psychiatry
April 27, 2022
Mazdak M. Bradberry, Natalie Gukasyan, Charles L. Raison
20 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
Frontiers in Psychiatry
April 25, 2022
Peter Oehen, Peter Gasser
70 citations
The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatment, and preliminary evidence of efficacy of the scheduled drug for the particular condition. Since 2014, the authors have obtained 50 licenses on a case-by-case basis and developed a psychedelic-assisted group therapy model utilizing MDMA and LSD....
International Journal of Drug Policy
April 1, 2022
Antonia Bendau, Leonard Viohl, Moritz Bruno Petzold et al.
The COVID-19 pandemic is presumably having an impact on the consumption of psychoactive substances. Social distancing and lockdown measures may particularly affect the use of "party drugs" (e.g., stimulants, dissociatives, and GHB/GBL) through the absence of typical use settings. We aimed to analyse the use patterns of those substances and underlying motivations before and during the pandemic....
Journal of Neuroscience Research
April 1, 2022
Emilija Glavonic, Milos Mitic, Miroslav Adzic
20 citations
Fear-related disorders, mainly phobias and post-traumatic stress disorder, are highly prevalent, debilitating disorders that pose a significant public health problem. They are characterized by aberrant processing of aversive experiences and dysregulated fear extinction, leading to excessive expression of fear and diminished quality of life. The gold standard for treating fear-related disorders...
European Neuropsychopharmacology
April 1, 2022
Karolina E. Kolaczynska, Paula Ducret, Daniel Trachsel et al.
7 citations
3,4-methylenedioxyamphetamine (MDA) is a psychoactive compound chemically related to the entactogen MDMA. MDA shares some of the entactogenic effects of MDMA but also exerts stimulant effects and psychedelic properties at higher doses. Here, we examined the pharmacological properties of MDA analogs and related amphetamine-based compounds detected in street drug samples or in sport supplements....
Frontiers in Psychiatry
March 25, 2022
David E. Nichols
65 citations
At first glance, it appears there is little difference between the molecular structures of methylenedioxymethamphetamine (MDMA), which has an N -methyl attached to its amino group, and methylenedioxyamphetamine (MDA), a primary amine that is recognized to have hallucinogenic activity. It is known from studies with other hallucinogenic amphetamines that N -methylation of hallucinogenic...
Journal of Counseling & Development
March 19, 2022
Benjamin Hearn, Michael D. Brubaker, George B. Richardson
46 citations
Abstract The ‘‘psychedelic renaissance’’ is generating new evidence for psychedelics’ potential to treat numerous mental and substance use disorders. In particular, the United States Food and Drug Administration is poised to approve psychedelic drugs 3,4 methylenedioxymethamphetamine (MDMA) and psilocybin for the use in psychedelic‐assisted therapy (PAT). This renaissance has led to substantial...
Australian & New Zealand Journal of Psychiatry
March 12, 2022
Steve Kisely, Mark Connor, Andrew A Somogyi et al.
36 citations
Objectives: There is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed,...
Psychopharmacology
March 7, 2022
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm et al.
85 citations
As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.
Psychopharmacology
March 1, 2022
Madeline M. Pantoni, Jinah L. Kim, Kaitlin R. Van Alstyne et al.
Abstract Rationale ±3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that shows substantial promise as a psychotherapeutic agent. Still, there is some concern regarding its behavioral toxicity, and its dose-effect relationship is poorly understood. We previously explored the role of dose in the cognitive effects of MDMA in a systematic review of existing literature and found no...
Clinical drug investigation
March 1, 2022
Anton L. V. Avanceña, J. Kahn, Elliot Marseille
19 citations
Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to psychotherapy with placebo. This study estimates potential costs, health benefits, and net savings of expanding access to MDMA-AT to eligible US patients with chronic and severe PTSD. Using a...
Journal of Psychopharmacology
March 1, 2022
Harriet de Wit, Anya K. Bershad, Charles S. Grob
11 citations
Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drugs change mood or behavior are poorly understood. Controlled laboratory studies with well-defined psychological constructs are valuable to understand how these drugs manifest their therapeutic benefit. However, there are substantial methodological...
Journal of Psychoactive Drugs
February 28, 2022
Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al.
47 citations
There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the "Psychedelic Renaissance." This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain...
PLoS One
February 25, 2022
Elliot Marseille, Jennifer Mitchell, James G. Kahn
49 citations
Background Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study updates the cost-effectiveness analysis of this novel therapy using data from a new phase 3...
Journal of Clinical Medicine
February 15, 2022
Lourdes Poyatos, A Acuna Torres, Esther Papaseit et al.
26 citations
Introduction and objective: Assessing the abuse potential of new substances with central nervous system activity is essential for preventing possible risks of misuse and addiction. The same methodology is recommended for the evaluation of the abuse potential of recreational drugs. This systematic review aims to assess the pharmacological effects related to the abuse potential and...
Journal of Psychopharmacology
February 15, 2022
Jessica L Maples-Keller, Seth D. Norrholm, Mark Burton et al.
53 citations
Background: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. Aims: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. Methods:...